• Je něco špatně v tomto záznamu ?

Association of triple positivity with prognostic parameters and overall survival in a population-based study of 6,122 HER2-positive breast cancer patients: analysis of real-world clinical practice based on a research database

I. Kolarova, J. Vanasek, M. Dolezel, J. Stuk, A. Hlavka, L. Dusek, B. Melichar, T. Büchler, A. Ryska, J. Prausova, K. Petrakova, P. Tesarova, J. Petera, M. Vosmik, K. Horackova, J. Jarkovsky

. 2020 ; 67 (6) : 1373-1383. [pub] 20200701

Jazyk angličtina Země Slovensko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21011955

Triple-positive breast cancer (TPBC), i.e. HER2-positive (HER2+) and hormone receptors-positive breast cancer, is a specific subgroup of breast cancers. TPBC biology is characterized by strong mutual interactions between signaling pathways stimulated by estrogens and HER2 amplification. The present study aims to carry out a population-based analysis of treatment outcomes in a cohort of hormone receptor (HR) positive and negative breast cancer patients who were treated with anti-HER2 therapy in the Czech Republic. The BREAST research database was used as the data source for this retrospective analysis. The database covers approximately 95% of breast cancer patients treated with targeted therapies in the Czech Republic. The analysis included 6,122 HER2-positive patients. The patients were divided into two groups, based on estrogen receptor (ER) or progesterone receptor (PR) positivity: hormone receptor negative (HR-) patients had both ER- and PR-negative tumors (n=2,518), unlike positive (HR+) patients (n=3,604). HR+ patients were more often diagnosed premenopausal at the time of diagnosis, presented more often at stage I or II and their tumors were less commonly poorly differentiated. The overall survival (OS) was significantly higher in subgroups of HR+ patients according to treatment setting. When evaluated by stages, significantly higher OS was observed in HR+ patients diagnosed at stages II, III, and IV and regardless of tumor grade.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21011955
003      
CZ-PrNML
005      
20210714131159.0
007      
ta
008      
210420s2020 xo f 000 0|eng||
009      
AR
024    7_
$a 10.4149/neo_2020_191023N1080 $2 doi
035    __
$a (PubMed)32614235
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xo
100    1_
$a Kolarova, I $u Department of Oncology and Radiotherapy, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic ; Faculty of Health Studies, University of Pardubice, Pardubice, Czech Republic
245    10
$a Association of triple positivity with prognostic parameters and overall survival in a population-based study of 6,122 HER2-positive breast cancer patients: analysis of real-world clinical practice based on a research database / $c I. Kolarova, J. Vanasek, M. Dolezel, J. Stuk, A. Hlavka, L. Dusek, B. Melichar, T. Büchler, A. Ryska, J. Prausova, K. Petrakova, P. Tesarova, J. Petera, M. Vosmik, K. Horackova, J. Jarkovsky
520    9_
$a Triple-positive breast cancer (TPBC), i.e. HER2-positive (HER2+) and hormone receptors-positive breast cancer, is a specific subgroup of breast cancers. TPBC biology is characterized by strong mutual interactions between signaling pathways stimulated by estrogens and HER2 amplification. The present study aims to carry out a population-based analysis of treatment outcomes in a cohort of hormone receptor (HR) positive and negative breast cancer patients who were treated with anti-HER2 therapy in the Czech Republic. The BREAST research database was used as the data source for this retrospective analysis. The database covers approximately 95% of breast cancer patients treated with targeted therapies in the Czech Republic. The analysis included 6,122 HER2-positive patients. The patients were divided into two groups, based on estrogen receptor (ER) or progesterone receptor (PR) positivity: hormone receptor negative (HR-) patients had both ER- and PR-negative tumors (n=2,518), unlike positive (HR+) patients (n=3,604). HR+ patients were more often diagnosed premenopausal at the time of diagnosis, presented more often at stage I or II and their tumors were less commonly poorly differentiated. The overall survival (OS) was significantly higher in subgroups of HR+ patients according to treatment setting. When evaluated by stages, significantly higher OS was observed in HR+ patients diagnosed at stages II, III, and IV and regardless of tumor grade.
650    _2
$a nádorové biomarkery $7 D014408
650    12
$a nádory prsu $x farmakoterapie $x genetika $7 D001943
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a prognóza $7 D011379
650    _2
$a receptor erbB-2 $x antagonisté a inhibitory $x genetika $7 D018719
650    _2
$a receptory pro estrogeny $x genetika $7 D011960
650    _2
$a receptory progesteronu $x genetika $7 D011980
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a míra přežití $7 D015996
651    _2
$a Česká republika $7 D018153
655    _2
$a časopisecké články $7 D016428
700    1_
$a Vanasek, J $u Faculty of Health Studies, University of Pardubice, Pardubice, Czech Republic ; Department of Medical and Radiation Oncology, Pardubice Hospital, Pardubice, Czech Republic ; Radiology Centre Multiscan, Ltd., Pardubice, Czech Republic
700    1_
$a Dolezel, M $u Department of Oncology, Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic $u First Faculty of Medicine, Charles University, Prague, Czech Republic $u Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
700    1_
$a Stuk, J $u Radiology Centre Multiscan, Ltd., Pardubice, Czech Republic
700    1_
$a Hlavka, A $u Department of Medical and Radiation Oncology, Pardubice Hospital, Pardubice, Czech Republic $u Radiology Centre Multiscan, Ltd., Pardubice, Czech Republic
700    1_
$a Dusek, L $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Melichar, B $u Department of Oncology and Radiotherapy, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic ; Department of Oncology, Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic ; Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic ; Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
700    1_
$a Büchler, T $u Department of Oncology, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic
700    1_
$a Ryska, A $u The Fingerland Department of Pathology, Faculty of Medicine, Charles University and University Hospital Hradec Kralove, Czech Republic
700    1_
$a Prausova, J $u Department of Oncology, University Hospital in Motol, Prague, Czech Republic
700    1_
$a Petrakova, K $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Tesarova, P $u First Faculty of Medicine, Charles University, Prague, Czech Republic ; Department of Oncology, General University Hospital in Prague, Prague, Czech Republic
700    1_
$a Petera, J $u Department of Oncology and Radiotherapy, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic ; Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
700    1_
$a Vosmik, M $u Department of Oncology and Radiotherapy, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic ; Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
700    1_
$a Horackova, K $u Faculty of Health Studies, University of Pardubice, Pardubice, Czech Republic
700    1_
$a Jarkovsky, J $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic
773    0_
$w MED00003470 $t Neoplasma $x 0028-2685 $g Roč. 67, č. 6 (2020), s. 1373-1383
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32614235 $y Pubmed
910    __
$a ABA008 $b A 1194 $c 659 $y p $z 0
990    __
$a 20210420 $b ABA008
991    __
$a 20210714131157 $b ABA008
999    __
$a ok $b bmc $g 1650351 $s 1132334
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 67 $c 6 $d 1373-1383 $e 20200701 $i 0028-2685 $m Neoplasma $n Neoplasma $x MED00003470
LZP    __
$a Pubmed-20210420

Najít záznam

Citační ukazatele

Možnosti archivace